Independent Medical Education Grants in Metastatic Hormone Sensitive Prostate Cancer
AstraZeneca funds independent medical education on metastatic hormone sensitive prostate cancer, with a focus on new therapies, resistance, and patient selection to improve care.
Funder: AstraZeneca United States
Due Dates: August 1, 2026 (Full application deadline)
Funding Amounts: Up to $300,000 per program; typically 1-year duration.
Summary: Supports independent medical education initiatives to advance knowledge and improve outcomes in metastatic hormone sensitive prostate cancer.
Key Information: Programs must be accredited, non-promotional, and comply with ACCME and FDA guidance.
Description
AstraZeneca United States, through its Medical Education Grants Office (MEGO), is soliciting proposals for independent medical education (IME/CME) grants focused on metastatic hormone sensitive prostate cancer (mHSPC). The initiative aims to address significant unmet needs in this therapeutic area, with an emphasis on improving durable responses, expanding treatment options, and refining patient selection via clinical and molecular markers. Priority is given to educational programs that further understanding of emerging combination therapies (e.g., ARPIs with PARP inhibitors), resistance mechanisms, and long-term tolerability. The ultimate goal is to improve patient care by equipping healthcare professionals with up-to-date, scientifically rigorous knowledge.
